Fig. 1 · Structure
Documents & Downloads
Belantamab mafodotin
Anti-BCMA ADC
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B cell maturation antigen (BCMA), designed to deliver cytotoxic agents directly to malignant plasma cells. The compound comprises a humanized monoclonal antibody linked to McMMAF, facilitating targeted therapy in multiple myeloma. Belantamab mafodotin exhibits significant anti-myeloma activity, making it a valuable reagent for research in cancer biology and therapeutic development.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 2050232-20-5 |
| Applications | Anti-BCMA ADC |
| Molecular Weight | 149000 (average) |
| Synonyms | GSK2857916; Belantamab mafodotin-blm |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.